Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Sees Significant Drop in Short Interest

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) was the recipient of a significant drop in short interest in December. As of December 15th, there was short interest totaling 25,588 shares, a drop of 23.5% from the November 30th total of 33,462 shares. Based on an average daily volume of 3,281,479 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.2% of the company’s shares are sold short. Approximately 0.2% of the company’s shares are sold short. Based on an average daily volume of 3,281,479 shares, the days-to-cover ratio is currently 0.0 days.

Analyst Ratings Changes

Several research analysts have issued reports on the company. B. Riley reiterated a “buy” rating and issued a $16.00 price target (up previously from $13.00) on shares of Radiopharm Theranostics in a report on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $15.33.

Institutional Trading of Radiopharm Theranostics

A hedge fund recently raised its stake in Radiopharm Theranostics stock. PNC Financial Services Group Inc. boosted its position in shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) by 100.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,000 shares of the company’s stock after purchasing an additional 8,000 shares during the period. PNC Financial Services Group Inc. owned about 0.20% of Radiopharm Theranostics worth $88,000 as of its most recent SEC filing.

Radiopharm Theranostics Price Performance

Shares of NASDAQ RADX traded down $0.21 during midday trading on Tuesday, hitting $5.16. 67,994 shares of the company traded hands, compared to its average volume of 247,236. Radiopharm Theranostics has a 12-month low of $3.50 and a 12-month high of $16.25. The stock has a 50-day moving average price of $5.01 and a 200 day moving average price of $5.27.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.